Non Hodgkin Lymphoma Clinical Trial
A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin’s Lymphoma (cHL), Relapsed or Refractory From First Line Treatment
Summary
The purpose of this study is to determine whether nivolumab plus brentuximab vedotin (followed by brentuximab vedotin plus bendamustine in patient with suboptimal response) is safe and effective in treating patients with Hodgkin's lymphoma (cHL). Eligible patients are children, adolescents, and young adults relapsed or refractory to first line.
Eligibility Criteria
Inclusion Criteria:
Classic Hodgkin Lymphoma (cHL), relapsed or refractory
Minimal limitation on activities of daily living as measured by Karnofsky ≥ 50 for participants > 16 years of age or Lansky ≥ 50 for participants ≤ 16 years of age.
One prior anti-cancer therapy that did not work
Exclusion Criteria:
Active, known, or suspected autoimmune disease or infection
Active cerebral/meningeal disease related to the underlying malignancy
More than one line of anti-cancer therapy or no treatment at all
Received a stem cell transplant for Hodgkin Lymphoma and/or a solid organ transplant
Prior treatment with any drug that targets T cell co-stimulation pathways (such as checkpoint inhibitors)
Other protocol defined inclusion/exclusion criteria apply
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 79 Locations for this study
Birmingham Alabama, 35233, United States
Phoenix Arizona, 85016, United States
Loma Linda California, 92350, United States
Madera California, 93636, United States
Oakland California, 94609, United States
Orange California, 92868, United States
Palo Alto California, 94304, United States
San Diego California, 92109, United States
Aurora Colorado, 80045, United States
New Haven Connecticut, 06520, United States
Wilmington Delaware, 19803, United States
Washington District of Columbia, 20010, United States
Jacksonville Florida, 32207, United States
Saint Petersburg Florida, 33701, United States
Atlanta Georgia, 30322, United States
Iowa City Iowa, 52242, United States
Baltimore Maryland, 21287, United States
Boston Massachusetts, 02215, United States
Detroit Michigan, 48201, United States
Jackson Mississippi, 39216, United States
Kansas City Missouri, 64108, United States
Saint Louis Missouri, 63110, United States
Las Vegas Nevada, 89135, United States
Hackensack New Jersey, 07601, United States
New Brunswick New Jersey, 08903, United States
Buffalo New York, 14263, United States
Chapel Hill North Carolina, 27599, United States
Charlotte North Carolina, 28203, United States
Cincinnati Ohio, 45229, United States
Columbus Ohio, 43205, United States
Oklahoma City Oklahoma, 73104, United States
Hershey Pennsylvania, 17033, United States
Philadelphia Pennsylvania, 19104, United States
Pittsburgh Pennsylvania, 15224, United States
Nashville Tennessee, 37232, United States
Austin Texas, 78723, United States
Dallas Texas, 75235, United States
Houston Texas, 77030, United States
Salt Lake City Utah, 84113, United States
Norfolk Virginia, 23507, United States
Richmond Virginia, 23219, United States
Seattle Washington, 98105, United States
Milwaukee Wisconsin, 53226, United States
Calgary Alberta, T3B 6, Canada
Toronto Ontario, M5G 1, Canada
Montreal Quebec, H4A 3, Canada
Praha 5 , 150 0, Czechia
Vandoeuvre lès Nancy Meurthe-et-Moselle, 54511, France
Lille , 59037, France
Lyon Cedex 08 , 69008, France
Marseille , 13011, France
Nantes , 44093, France
Paris Cedex 12 , 75571, France
Paris , 75019, France
Toulouse cedex 9 , 31059, France
Villejuif , 94805, France
Berlin , 13353, Germany
Giessen , 35392, Germany
Hannover , 30625, Germany
Muenchen , 80337, Germany
Dublin , Dubli, Ireland
Aviano (PN) , 33081, Italy
Bologna , 40138, Italy
Genova , 16147, Italy
Monza (mb) , 20900, Italy
Napoli , 80123, Italy
Roma , 00161, Italy
Rotterdam , 3015 , Netherlands
Utrecht , 3584 , Netherlands
Gdansk , 80-95, Poland
Krakow , 30-66, Poland
Barcelona , 08950, Spain
Madrid , 28009, Spain
Leeds North Yorkshire, LS1 3, United Kingdom
Leeds Yorkshire, LS9 7, United Kingdom
Birmingham , B15 2, United Kingdom
Glasgow , G51 4, United Kingdom
London , NW1 2, United Kingdom
Manchester , M13 9, United Kingdom
How clear is this clinincal trial information?